| Year |
Citation |
Score |
| 2023 |
McKinney LP, Singh R, Jordan IK, Varambally S, Dammer EB, Lillard JW. Transcriptome Analysis Identifies Tumor Immune Microenvironment Signaling Networks Supporting Metastatic Castration-Resistant Prostate Cancer. Onco. 3: 81-95. PMID 38435029 DOI: 10.3390/onco3020007 |
0.635 |
|
| 2022 |
Adebayo OO, Dammer EB, Dill CD, Adebayo AO, Oseni SO, Griffen TL, Ohandjo AQ, Yan F, Jain S, Barwick BG, Singh R, Boise LH, Lillard JW. Multivariant Transcriptome Analysis Identifies Modules and Hub Genes Associated with Poor Outcomes in Newly Diagnosed Multiple Myeloma Patients. Cancers. 14. PMID 35565356 DOI: 10.3390/cancers14092228 |
0.789 |
|
| 2022 |
Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer Journal. 12: 43. PMID 35301276 DOI: 10.1038/s41408-022-00623-7 |
0.716 |
|
| 2021 |
Nunez SK, Young CD, Griffen TL, Ohandjo AQ, McKinney LP, Kopetz S, Lillard JW. Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer. Cancers. 13. PMID 34830978 DOI: 10.3390/cancers13225824 |
0.798 |
|
| 2021 |
van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, de Bont ESJM, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. PMID 34625713 DOI: 10.1038/s41375-021-01438-4 |
0.721 |
|
| 2021 |
Griffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Nunez SK, Ohandjo AQ, Kornblau SM, Lillard JW. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. Bmc Medical Genomics. 14: 171. PMID 34187466 DOI: 10.1186/s12920-021-01012-y |
0.752 |
|
| 2021 |
Dill CD, Dammer EB, Griffen TL, Seyfried NT, Lillard JW. A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer. Iscience. 24: 102451. PMID 34007962 DOI: 10.1016/j.isci.2021.102451 |
0.799 |
|
| 2020 |
Singh SK, Gordetsky JB, Bae S, Acosta EP, Lillard JW, Singh R. Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer. Cells. 9. PMID 32867229 DOI: 10.3390/Cells9091976 |
0.389 |
|
| 2020 |
Noel B, Singh SK, Lillard JW, Singh R. Role of natural compounds in preventing and treating breast cancer. Frontiers in Bioscience (Scholar Edition). 12: 137-160. PMID 32114452 DOI: 10.2741/S544 |
0.364 |
|
| 2020 |
Thomas JK, Kapur N, Mir H, Gales DN, Lillard JW, Singh S. Abstract C113: Antibody microarray analysis of signaling networks regulated by the CCR9/CCL25 axis in African American and Caucasian American triple-negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-C113 |
0.387 |
|
| 2020 |
Adebayo OO, Griffen T, Young C, Dammer E, Lillard JW. Abstract 4388: Weighted gene co-expression network analysis identified cell cycle signaling pathway associated hub genes correlated with progression and prognosis of multiple myeloma Cancer Research. 80: 4388-4388. DOI: 10.1158/1538-7445.Am2020-4388 |
0.795 |
|
| 2019 |
Ohandjo AQ, Liu Z, Dammer EB, Dill CD, Griffen TL, Carey KM, Hinton DE, Meller R, Lillard JW. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment. Scientific Reports. 9: 14963. PMID 31628349 DOI: 10.1038/S41598-019-46491-3 |
0.806 |
|
| 2019 |
Huang MB, Wu JY, Lillard J, Bond VC. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells. Oncotarget. 10: 5419-5438. PMID 31534628 DOI: 10.18632/Oncotarget.27138 |
0.352 |
|
| 2019 |
Kapur N, Mir H, Sonpavde G, Jain S, Bae S, Lillard JW, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Letters. PMID 30974114 DOI: 10.1016/J.Canlet.2019.04.001 |
0.42 |
|
| 2019 |
Mir H, Kaur G, Kapur N, Bae S, Lillard JW, Singh S. Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Scientific Reports. 9: 2527. PMID 30792527 DOI: 10.1038/S41598-019-38766-6 |
0.418 |
|
| 2019 |
Adebayo Oo, Young C, Griffen T, Carey K, Nunez S, Jain SR, Lillard J. Clinical significance of CXCR5-CXCL13 signaling in multiple myeloma. Journal of Clinical Oncology. 37: e19517-e19517. DOI: 10.1200/Jco.2019.37.15_Suppl.E19517 |
0.799 |
|
| 2019 |
Adebayo OO, Griffin T, Young C, Dill CD, Nunez S, Carey K, Lillard JW. Abstract LB-132: The role of CXCL13, its sole receptor CXCR5, and associated genes in multiple myeloma progression Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-132 |
0.775 |
|
| 2019 |
Huang MB, Wu JY, Roth WW, Lillard J, Bond VC. Abstract 2856: Secretion modification region (SMR) peptide blocks migration and invasion in human breast cancer cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2856 |
0.317 |
|
| 2019 |
Dill CD, Griffen T, Young C, Carey K, Lillard JW. Abstract 1975: Multivariate exome analysis identifies CXCR5-CXCL13 signaling as a key driver in early breast cancer development and prognosis Cancer Research. 79: 1975-1975. DOI: 10.1158/1538-7445.Sabcs18-1975 |
0.788 |
|
| 2019 |
Griffen T, Young C, Dill CD, Carey K, Adebayo O, Nunez S, Lillard J. Abstract 1972: CXCR5-CXCL13 signaling contributes to CLL relapse and patient survival Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1972 |
0.756 |
|
| 2019 |
Carey K, Griffen T, Young C, Dill C, Lillard J. Abstract 1971: A multi-variate transcriptome analysis of CXCR5-CXCL13 signaling in ovarian cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1971 |
0.764 |
|
| 2019 |
Anwanwan D, Singh SK, Lillard JW, Mishra MK, Singh R. Abstract 4412: Piperine enhances the efficacy of 5 FU against liver cancer Cancer Research. 79: 4412-4412. DOI: 10.1158/1538-7445.Am2019-4412 |
0.361 |
|
| 2019 |
Yi B, Li X, Xu Z, Bae S, Wei S, Liu R, Lillard J, Wang L. Abstract 1021: CD24 dependent inactivation of mutant p53 in metastatic castration resistant prostate cancer Cancer Research. 79: 1021-1021. DOI: 10.1158/1538-7445.Am2019-1021 |
0.327 |
|
| 2018 |
Singh SK, Lillard JW, Singh R. Title: Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer. Cancer Letters. PMID 29678549 DOI: 10.1016/J.Canlet.2018.04.017 |
0.362 |
|
| 2018 |
Singh SK, Mishra MK, Eltoum IA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Scientific Reports. 8: 1323. PMID 29358632 DOI: 10.1038/S41598-018-19643-0 |
0.386 |
|
| 2018 |
Khamit-Kush KK, Lillard JW, Bond VC, Huang M, Roth W. Abstract A42: Identifying relationships between high expression levels of the HSPA9 gene, putative HSPA9 alterations, and patient survivability in invasive breast carcinomas Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-A42 |
0.456 |
|
| 2018 |
Singh SK, Lillard JW, Singh R. Abstract B70: Thymoquinone regulates cytochrome P450 genes involved in prostate cancer disparity Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B70 |
0.398 |
|
| 2018 |
Ohandjo AQ, Dill C, Dongquan C, Lillard JW. Abstract B56: Regulation of CXCR5-CXCL13 signaling in prostate cancer etiologic disparities Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B56 |
0.625 |
|
| 2018 |
Dill CD, Okoro A, Chen D, Lillard JW. Abstract B50: The role of CXCL13-CXCR5 signaling in triple-negative breast cancer progression Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B50 |
0.707 |
|
| 2018 |
Gales DN, Mir H, Kapur N, Lillard JW, Singh S. Abstract 5080: ADAM10 promotes breast cancer via CXCL16 constitutive cleavage and CXCR6 signaling Tumor Biology. DOI: 10.1158/1538-7445.Am2018-5080 |
0.389 |
|
| 2018 |
Mir H, Kapur N, Lillard JW, Singh S. Abstract 1924: Role of CXCL16 and ADAM10 in ovarian cancer pathogenesis Cancer Research. 78: 1924-1924. DOI: 10.1158/1538-7445.Am2018-1924 |
0.448 |
|
| 2017 |
Singh SK, Singh S, Lillard JW, Singh R. Drug delivery approaches for breast cancer. International Journal of Nanomedicine. 12: 6205-6218. PMID 28883730 DOI: 10.2147/Ijn.S140325 |
0.308 |
|
| 2017 |
Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway. Oncotarget. PMID 28212547 DOI: 10.18632/Oncotarget.15303 |
0.37 |
|
| 2017 |
Huang MB, Gonzalez RR, Lillard J, Bond VC. Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. Oncotarget. PMID 28076321 DOI: 10.18632/Oncotarget.14513 |
0.339 |
|
| 2017 |
Singh SK, Lillard JW, Singh R. Molecular basis for prostate cancer racial disparities. Frontiers in Bioscience (Landmark Edition). 22: 428-450. PMID 27814623 DOI: 10.2741/4493 |
0.348 |
|
| 2017 |
McGarity D, Epps B, Maynor A, Anderson T, Alema-Mensah E, Fray D, Aung M, Holden K, Lillard J, Rivers B, Beech D. Abstract 768: The utility of a breast cancer registry for improved cancer management in developing countries Cancer Research. 77: 768-768. DOI: 10.1158/1538-7445.Am2017-768 |
0.338 |
|
| 2016 |
Kapur N, Mir H, Clark Iii CE, Krishnamurti U, Beech DJ, Lillard JW, Singh S. CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. British Journal of Cancer. PMID 27149649 DOI: 10.1038/Bjc.2016.113 |
0.424 |
|
| 2016 |
Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle (Georgetown, Tex.). 15: 819-26. PMID 27029529 DOI: 10.1080/15384101.2016.1148836 |
0.368 |
|
| 2016 |
Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering. Oncotarget. PMID 26799186 DOI: 10.18632/Oncotarget.6944 |
0.405 |
|
| 2016 |
Daley-Brown D, Oprea-Ilies G, Lee R, Vann KT, Lanier V, Quarshie A, Lillard J, Pattillo R, Gonzalez-Perez RR. Abstract C78: NILCO: A marker for obesity-related endometrial cancer in African American women Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-C78 |
0.324 |
|
| 2016 |
Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Abstract 5254: Andrographolide prevents prostate cancer by targeting CXCR3/CXCR7 and regulators of cell cycle Cancer Research. 76: 5254-5254. DOI: 10.1158/1538-7445.Am2016-5254 |
0.392 |
|
| 2016 |
Singh SK, Banerjee S, Lillard JW, Singh R. Abstract 5043: Molecular mechanism of resveratrol induced cell death in multidrug resistance prostate cancer Cancer Research. 76: 5043-5043. DOI: 10.1158/1538-7445.Am2016-5043 |
0.387 |
|
| 2016 |
Banerjee S, Singh SK, Lillard JW, Singh R. Abstract 3841: Curcumin enhances the efficacy of docetaxel- induced apoptosis of prostate cancer cell Cancer Research. 76: 3841-3841. DOI: 10.1158/1538-7445.Am2016-3841 |
0.364 |
|
| 2016 |
Hinton DE, Lillard J. Abstract 1838: Differential CXCL13 and CXCR5 expression mediated by down-regulation of select miRNAs in prostate cancer Cancer Research. 76: 1838-1838. DOI: 10.1158/1538-7445.Am2016-1838 |
0.395 |
|
| 2016 |
Kapur N, Mir H, Clark CE, Krishnamurti U, Beech DJ, Lillard JW, Singh S. Abstract 1701: CCR6 associates with colon cancer metastasis Cancer Research. 76: 1701-1701. DOI: 10.1158/1538-7445.Am2016-1701 |
0.405 |
|
| 2016 |
Daley-Brown D, Oprea-Ilies G, Vann KT, Pattillo R, Lillard J, Gonzalez-Perez RR. Abstract 1008: Leptin-induced NILCO in endometrial cancer is linked to obesity Cancer Research. 76: 1008-1008. DOI: 10.1158/1538-7445.Am2016-1008 |
0.313 |
|
| 2015 |
Zhang W, Yi B, Wang C, Chen D, Bae S, Wei S, Guo RJ, Lu C, Nguyen LL, Yang WH, Lillard JW, Zhang X, Wang L, Liu R. Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26712693 DOI: 10.1158/1078-0432.Ccr-15-1927 |
0.351 |
|
| 2015 |
Mir H, Singh R, Kloecker GH, Lillard JW, Singh S. CXCR6 expression in non-small cell lung carcinoma supports metastatic process via modulating metalloproteinases. Oncotarget. 6: 9985-98. PMID 25888629 DOI: 10.18632/Oncotarget.3194 |
0.383 |
|
| 2015 |
Singh R, Singh S, Sonpavde GP, Lillard JW. Abstract 5531: Combination drug delivery using PBM nanoparticle to improve prostate cancer therapy Cancer Research. 75: 5531-5531. DOI: 10.1158/1538-7445.Am2015-5531 |
0.366 |
|
| 2015 |
Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Abstract 5362: Andrographolide inhibits prostate cancer by modulating chemokine and cytokines Cancer Research. 75: 5362-5362. DOI: 10.1158/1538-7445.Am2015-5362 |
0.393 |
|
| 2015 |
Carriere PP, Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Abstract 4107: CCR9/CCL25 mediates epithelial-mesenchymal transition in prostate cancer Cancer Research. 75: 4107-4107. DOI: 10.1158/1538-7445.Am2015-4107 |
0.441 |
|
| 2015 |
Ahabue B, Pullen P, Ogbesor A, Seffens WS, Lillard JW. Abstract 3740: Exergame development for cancer prevention and intervention Cancer Research. 75: 3740-3740. DOI: 10.1158/1538-7445.Am2015-3740 |
0.333 |
|
| 2015 |
Yoo W, Rust G, Zhang S, Lillard J. Abstract 3701: Health disparity characteristics on growth patterns of breast cancer mortality trends among the US Counties, 1989-2010 Cancer Research. 75: 3701-3701. DOI: 10.1158/1538-7445.Am2015-3701 |
0.339 |
|
| 2014 |
Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JW, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 5: 10170-9. PMID 25296976 DOI: 10.18632/Oncotarget.2526 |
0.377 |
|
| 2014 |
Singh R, Lillard JW. Abstract 4476: Targeted delivery of curcumin to improve therapeutic outcome in breast cancer Cancer Research. 74: 4476-4476. DOI: 10.1158/1538-7445.Am2014-4476 |
0.359 |
|
| 2014 |
Gupta P, Ward AB, Mir H, Kaur G, Grizzle WE, Lillard JW, Singh S. Abstract 4047: Potential role of CXCR6-CXCL16 in prostate cancer progression and chemotherapeutic efficacy Cancer Research. 74: 4047-4047. DOI: 10.1158/1538-7445.Am2014-4047 |
0.455 |
|
| 2014 |
Mir H, Gupta P, Singh R, Sharma PK, Kaur G, Ward AB, Grizzle WE, Lillard JW, Singh S. Abstract 4003: Clinical and biological significance of CXCR6 in lung cancer Cancer Research. 74: 4003-4003. DOI: 10.1158/1538-7445.Am2014-4003 |
0.4 |
|
| 2014 |
Ward AB, Gupta P, Kaur G, Mir H, Lillard JW, Singh S. Abstract 2128: The effects of Quercetin on prostate cancer Cancer Research. 74: 2128-2128. DOI: 10.1158/1538-7445.Am2014-2128 |
0.411 |
|
| 2013 |
El-Haibi CP, Sharma P, Singh R, Gupta P, Taub DD, Singh S, Lillard JW. Differential G protein subunit expression by prostate cancer cells and their interaction with CXCR5. Molecular Cancer. 12: 64. PMID 23773523 DOI: 10.1186/1476-4598-12-64 |
0.381 |
|
| 2013 |
Singh R, Gupta P, Grizzle WE, Lillard JW, Singh S. Abstract 5121: Differential expression of CC chemokine receptor-9 in prostate cancer. Cancer Research. 73: 5121-5121. DOI: 10.1158/1538-7445.Am2013-5121 |
0.391 |
|
| 2013 |
Singh R, Gupta P, Singh S, Lillard JW. Abstract 4516: Targeted delivery of resveratrol to improve therapeutic outcome in prostate cancer. Cancer Research. 73: 4516-4516. DOI: 10.1158/1538-7445.Am2013-4516 |
0.365 |
|
| 2012 |
El-Haibi CP, Singh R, Gupta P, Sharma PK, Greenleaf KN, Singh S, Lillard JW. Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer. Journal of Proteomics & Bioinformatics. 5: 177-184. PMID 24009409 DOI: 10.4172/Jpb.1000232 |
0.437 |
|
| 2012 |
Singh R, Singh S, Briles DE, Taub DD, Hollingshead SK, Lillard JW. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine. 30: 1181-90. PMID 22178100 DOI: 10.1016/J.Vaccine.2011.12.020 |
0.316 |
|
| 2012 |
Singh R, Grizzle WE, Lillard JW, Singh S. Abstract 586: Withaferin-A inhibits prostate tumor growth by enhancing anti-tumor immune response Cancer Research. 72: 586-586. DOI: 10.1158/1538-7445.Am2012-586 |
0.386 |
|
| 2012 |
Singh R, Grizzle WE, Singh S, Lillard JW. Abstract 3649: Expression of CXCR5 and its natural ligand CXCL13 in ovarian cancer Cancer Research. 72: 3649-3649. DOI: 10.1158/1538-7445.Am2012-3649 |
0.447 |
|
| 2012 |
Lillard JW, Singh S, Singh R. Abstract A38: Nanoreformulation of platinum-based drugs to address disparate cancer treatment outcomes. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-A38 |
0.375 |
|
| 2011 |
Singh R, Stockard CR, Grizzle WE, Lillard JW, Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. International Journal of Oncology. 39: 373-81. PMID 21637913 DOI: 10.3892/Ijo.2011.1059 |
0.319 |
|
| 2011 |
Singh R, Lillard JW, Singh S. Chemokines: key players in cancer progression and metastasis. Frontiers in Bioscience (Scholar Edition). 3: 1569-82. PMID 21622291 DOI: 10.2741/246 |
0.385 |
|
| 2011 |
Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World Journal of Surgical Oncology. 9: 46. PMID 21539750 DOI: 10.1186/1477-7819-9-46 |
0.415 |
|
| 2011 |
Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JW. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. International Journal of Oncology. 38: 1279-85. PMID 21344163 DOI: 10.3892/Ijo.2011.953 |
0.404 |
|
| 2011 |
Singh R, Singh S, Grizzle WE, Lillard JW. Abstract 5257: Expression and functional role of CXCR5 and CXCL13 in non-small cell lung carcinoma (NSCLC) Cancer Research. 71: 5257-5257. DOI: 10.1158/1538-7445.Am2011-5257 |
0.406 |
|
| 2011 |
Singh R, Lillard JW, Grizzle WE, Singh S. Abstract 5247: Expression and functional role of CCR9 in lung cancer Cancer Research. 71: 5247-5247. DOI: 10.1158/1538-7445.Am2011-5247 |
0.388 |
|
| 2011 |
Kidd LR, Beache SC, Zheng J, Brock G, Lillard JW, Rudd J, Kimbro KS. Abstract 2780: Chemokine and chemokine receptor genetic variants as predictors of aggressive prostate cancer among European-American men Cancer Research. 71: 2780-2780. DOI: 10.1158/1538-7445.Am2011-2780 |
0.405 |
|
| 2011 |
El-Haibi CP, Singh R, Sharma PK, Singh S, Lillard JW. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation Cell Proliferation. 44: 311-319. DOI: 10.1111/J.1365-2184.2011.00757.X |
0.374 |
|
| 2010 |
Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World Journal of Surgical Oncology. 8: 62. PMID 20649989 DOI: 10.1186/1477-7819-8-62 |
0.376 |
|
| 2010 |
Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JW, Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. Journal of Ovarian Research. 3: 15. PMID 20565782 DOI: 10.1186/1757-2215-3-15 |
0.393 |
|
| 2010 |
El Haibi CP, Sharma PK, Singh R, Johnson PR, Suttles J, Singh S, Lillard JW. PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Molecular Cancer. 9: 85. PMID 20412587 DOI: 10.1186/1476-4598-9-85 |
0.383 |
|
| 2010 |
VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, Lillard JW, Kittles RA, Kidd LC. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. The Prostate. 70: 341-52. PMID 19908237 DOI: 10.1002/Pros.21067 |
0.368 |
|
| 2010 |
Triplet A, Sharma PK, Singh R, Lillard JW, Grizle WE, Singh S. Abstract 5215: CXCR6-mediated cellular and molecular events involved in breast cancer cell migration and invasion Cancer Research. 70: 5215-5215. DOI: 10.1158/1538-7445.Am10-5215 |
0.4 |
|
| 2010 |
Lillard JW, Singh R, Singh S, Sharma PK. Abstract 3377: CXCL13-directed therapy against bone metastasis in hormone-refractory prostate cancer Cancer Research. 70: 3377-3377. DOI: 10.1158/1538-7445.Am10-3377 |
0.379 |
|
| 2010 |
Mosley LD, Singh R, Sharma PK, Triplett AS, Singh S, Lillard JW. Abstract 1907: Mechanisms mediated by CXCL12 signaling through CXCR4 and CXCR7 in breast cancer Cancer Research. 70: 1907-1907. DOI: 10.1158/1538-7445.Am10-1907 |
0.439 |
|
| 2009 |
Harrington W, Bond V, Huang MB, Powell M, Lillard J, Manne U, Bumpers H. HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis. Molecular and Cellular Pharmacology. 1: 85-91. PMID 20383296 DOI: 10.4255/Mcpharmacol.09.10 |
0.344 |
|
| 2009 |
Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. International Journal of Cancer. Journal International Du Cancer. 125: 2288-95. PMID 19610059 DOI: 10.1002/Ijc.24574 |
0.373 |
|
| 2009 |
Singh S, Singh R, Sharma PK, Singh UP, Rai SN, Chung LW, Cooper CR, Novakovic KR, Grizzle WE, Lillard JW. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Letters. 283: 29-35. PMID 19375853 DOI: 10.1016/J.Canlet.2009.03.022 |
0.344 |
|
| 2009 |
Singh S, Bond VC, Powell M, Singh UP, Bumpers HL, Grizzle WE, Lillard JW. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth Molecular Cancer Therapeutics. 8: 178-184. PMID 19139127 DOI: 10.1158/1535-7163.Mct-08-0643 |
0.371 |
|
| 2009 |
Sharma PK, Singh R, Eaton JW, Lillard JW, Novakovic KR, Grizzle WE, Chung LWk, Singh S. Ccl25 Blockade Inhibits Anti-Apoptotic Signals In Prostate Cancer Cells And Enhances The Efficacy Of Etoposide The Journal of Urology. 181: 398-399. DOI: 10.1016/S0022-5347(09)61131-9 |
0.383 |
|
| 2008 |
Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 28: 31-43. PMID 18370870 DOI: 10.1089/Jir.2007.0059 |
0.312 |
|
| 2008 |
Zuba-Surma EK, Kucia M, Abdel-Latif A, Dawn B, Hall B, Singh R, Lillard JW, Ratajczak MZ. Morphological characterization of very small embryonic-like stem cells (VSELs) by ImageStream system analysis. Journal of Cellular and Molecular Medicine. 12: 292-303. PMID 18031297 DOI: 10.1111/J.1582-4934.2007.00154.X |
0.31 |
|
| 2008 |
Singh R, Singh S, Lillard JW. Prostate Cancer Cell-Specific Drug Targeting Using Novel Nanoparticles The Journal of Urology. 179: 230-230. DOI: 10.1016/S0022-5347(08)60663-1 |
0.324 |
|
| 2007 |
Singh UP, Venkataraman C, Singh R, Lillard JW. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocrine, Metabolic & Immune Disorders Drug Targets. 7: 111-23. PMID 17584151 DOI: 10.2174/187153007780832109 |
0.317 |
|
| 2006 |
Palaniappan R, Singh S, Singh UP, Singh R, Ades EW, Briles DE, Hollingshead SK, Royal W, Sampson JS, Stiles JK, Taub DD, Lillard JW. CCL5 modulates pneumococcal immunity and carriage. Journal of Immunology (Baltimore, Md. : 1950). 176: 2346-56. PMID 16455992 DOI: 10.4049/Jimmunol.176.4.2346 |
0.315 |
|
| 2006 |
Singh S, Singh R, Singh UP, Kimbro KS, Cooper CR, Chung LWK, Datta MW, Didier PJ, Grizzle WE, Lillard JW. 824: CXCR5-CXCL13 Expression Regulates Cellular Mechanisms Involved in Prostate Cancer Cell Migration, Invasion and Clinically Correlates with Prostate Cancer Progression The Journal of Urology. 175: 266-266. DOI: 10.1016/S0022-5347(18)33060-X |
0.392 |
|
| 2005 |
Sarfo BY, Armah HB, Irune I, Adjei AA, Olver CS, Singh S, Lillard JW, Stiles JK. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malaria Journal. 4: 63. PMID 16359553 DOI: 10.1186/1475-2875-4-63 |
0.32 |
|
| 2005 |
Bumpers HL, Huang MB, Powell M, Grizzle WE, Lillard JW, Okoli J, Bond VC. Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer. Cancer Biology & Therapy. 4: 65-9. PMID 15662115 DOI: 10.4161/Cbt.4.1.1377 |
0.315 |
|
| 2004 |
Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8743-50. PMID 15623660 DOI: 10.1158/1078-0432.Ccr-04-0266 |
0.427 |
|
| 2004 |
Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Laboratory Investigation; a Journal of Technical Methods and Pathology. 84: 1666-76. PMID 15467730 DOI: 10.1038/Labinvest.3700181 |
0.373 |
|
| 2004 |
Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, Lillard JW, Taub DD. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells Journal of Clinical Investigation. 114: 57-66. PMID 15232612 DOI: 10.1172/Jci21134 |
0.314 |
|
| 2001 |
Lillard JW, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. Journal of Immunology (Baltimore, Md. : 1950). 166: 162-9. PMID 11123289 DOI: 10.4049/Jimmunol.166.1.162 |
0.305 |
|
| 1999 |
Jones HA, Lillard JW, Perry RD. HmsT, a protein essential for expression of the haemin storage (Hms+) phenotype of Yersinia pestis. Microbiology (Reading, England). 145: 2117-2128. PMID 10463178 DOI: 10.1099/13500872-145-8-2117 |
0.318 |
|
| Show low-probability matches. |